ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD

Imagem de Miniatura
Arquivos
art_CHARYTAN_ESRD_After_Heart_Failure_Myocardial_Infarction_or_Stroke_2017.PDF (432.02 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO-ELSEVIER INC
Autores
CHARYTAN, David M.
SOLOMON, Scott D.
IVANOVICH, Peter
REMUZZI, Giuseppe
COOPER, Mark E.
MCGILL, Janet B.
PARVING, Hans-Henrik
PARFREY, Patrick
SINGH, Ajay K.
Citação
AMERICAN JOURNAL OF KIDNEY DISEASES, v.70, n.4, p.522-531, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: How cardiovascular (CV) events affect progression to end-stage renal disease (ESRD), particularly in the setting of type 2 diabetes, remains uncertain. Study Design: Observational study. Setting & Participants: 4,022 patients with type 2 diabetes, anemia, and chronic kidney disease from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Predictor: Postrandomization CV events. Outcomes: ESRD (defined as initiation of dialysis for > 30 days, kidney transplantation, or refusal or nonavailability of renal replacement therapy) and post-ESRD mortality within 30 days and during overall follow-up after an intercurrent CV event. Limitations: Population limited to clinical trial participants with diabetes and anemia. Results: 155 of 652 (23.8%) ESRD cases occurred after an intercurrent CV event; 110 (16.9%) cases followed heart failure, 28 (4.3%) followed myocardial infarction, 12 (1.84%) followed stroke, and 5 (0.77%) followed multiple CV events. ESRD rate was higher within 30 days in individuals with an intercurrent CV event compared with those without an intercurrent event (HR, 22.2; 95% CI, 17.0-29.0). Compared to no intercurrent CV events, relative risks for ESRD were higher after the occurrence of heart failure overall (HR, 3.4; 95% CI, 2.7-4.2) and at 30 days (HR, 20.1; 95% CI, 14.5-27.9) than after myocardial infarction or stroke (P < 0.001). Compared with individuals without pre-ESRD events, those with ESRD following intercurrent CV events were older, were more likely to have prior CV disease, and had higher (24.4 vs 23.1 mL/min/1.73 m(2); P = 0.01) baseline estimated glomerular filtration rates (eGFRs) and higher eGFRs at last measurement before ESRD (18.6 vs 15.2 mL/min/1.73 m(2); P < 0.001), whereas race, sex, and medication use were similar. Post-ESRD mortality was similar (P = 0.3) with and without preceding CV events. Conclusions: Most ESRD cases occurred in individuals without intercurrent CV events who had lower eGFRs than individuals with intercurrent CV events, but similar post-ESRD mortality. Nevertheless, intercurrent CV events, particularly heart failure, are strongly associated with risk for ESRD. These findings underscore the need for kidney-specific therapies in addition to treatment of CV risk factors to lower ESRD incidence in diabetes. (C) 2017 by the National Kidney Foundation, Inc.
Palavras-chave
Cardiovascular diseases, heart failure, kidney, myocardial infarction, cerebral infarction, end-stage renal disease (ESRD)
URI
https://observatorio.fm.usp.br/handle/OPI/21785
Referências
  1. Bock JS, 2010, CIRCULATION, V121, P2592, DOI 10.1161/CIRCULATIONAHA.109.886473
  2. Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905
  3. Charytan DM, 2015, AM J KIDNEY DIS, V66, P429, DOI 10.1053/j.ajkd.2015.02.324
  4. Chertow GM, 1998, AM J MED, V104, P343, DOI 10.1016/S0002-9343(98)00058-8
  5. Chertow GM, 1997, CIRCULATION, V95, P878
  6. Cho E, 2013, NEPHROL DIAL TRANSPL, V28, P2766, DOI 10.1093/ndt/gft376
  7. Crews DC, 2014, J AM SOC NEPHROL, V25, P370, DOI 10.1681/ASN.2013050567
  8. Desai AS, 2011, AM J KIDNEY DIS, V58, P717, DOI 10.1053/j.ajkd.2011.05.020
  9. Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
  10. Fox CS, 2012, LANCET, V380, P1662, DOI 10.1016/S0140-6736(12)61350-6
  11. Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
  12. Hillege HL, 2003, EUR HEART J, V24, P412, DOI 10.1016/S0195-668X(02)00526-2
  13. HOSTETTER TH, 1983, AM J PHYSIOL, V245, pH98
  14. ICHIKAWA I, 1984, CIRC RES, V55, P669
  15. Kim JH, 2014, AM J CARDIOL, V114, P1830, DOI 10.1016/j.amjcard.2014.09.022
  16. Landray MJ, 2010, AM J KIDNEY DIS, V56, P1082, DOI 10.1053/j.ajkd.2010.07.016
  17. Lekawanvijit S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083687
  18. Lekawanvijit S, 2012, AM J PHYSIOL-HEART C, V302, pH1884, DOI 10.1152/ajpheart.00967.2011
  19. Levey AS, 2006, ANN INTERN MED, V145, P247
  20. Levey AS, 2009, ANN INTERN MED, V150, P604
  21. Levey AS, 2003, ANN INTERN MED, V139, P137
  22. Levey AS, 2000, J AM SOC NEPHROL, V11, p155A
  23. Mcclellan WM, 2004, J AM SOC NEPHROL, V15, P1912, DOI 10.1097/01.asn.0000129982.10611.4c
  24. Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068
  25. Nadkarni GN, 2015, STROKE, V46, P3226, DOI 10.1161/STROKEAHA.115.010985
  26. Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845
  27. Sud M, 2015, J AM SOC NEPHROL, V26, P715, DOI 10.1681/ASN.2014030253
  28. Sud M, 2014, CIRCULATION, V130, P458, DOI 10.1161/CIRCULATIONAHA.113.007106
  29. Thamer M, 2015, AM J KIDNEY DIS, V66, P1024, DOI 10.1053/j.ajkd.2015.05.014
  30. Wagner M, 2011, AM J KIDNEY DIS, V57, P894, DOI 10.1053/j.ajkd.2010.12.023

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/12
Artigos e Materiais de Revistas Científicas - ODS/03